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Abstract
Background:  It has been observed that ras-transformed cell lines in culture have a higher
phosphatidylcholine (PC) biosynthesis rate as well as higher PC-degradation rate (increased PC-
turnover) than normal cells. In correspondence to these findings, the concentrations of the PC-
degradation product lyso-phosphatidylcholine (LPC) in cancer patients were found to be
decreased. Our objective was the systematic investigation of the relationship between LPC and
inflammatory and nutritional parameters in cancer patients. Therefore, plasma LPC concentrations
were assessed in 59 cancer patients and related to nutritional and inflammatory parameters. To
determine LPC in blood plasma we developed and validated a HPTLC method.
Results: Average plasma LPC concentration was 207 ± 59 μM which corresponds to the lower
limit of the reported range in healthy subjects. No correlation between LPC and age, performance
status, body mass index (BMI) or fat mass could be seen. However, LPC correlated inversely with
plasma C-reactive protein (CRP) and whole blood hydrogen peroxides (HPO). Further, a negative
correlation could be observed between LPC and whole body extra cellular fluid volume (ECF) as
well as with relative change in body weight since cancer diagnosis.
Conclusion: In conclusion, LPC concentrations were decreased in cancer patients. LPC plasma
concentrations correlated with weight loss and inflammatory parameters and, therefore, might be
a general indicator of severity of malignant disease.
Background
Phosphatidylcholine (PC), a glycerophospholipid bear-
ing a polar phosphocholine head group and two non-
polar fatty acid hydrocarbon chains, represents the main
membrane-forming phospholipid in mammalian cells.
Removal of one of the fatty acids, enzymatically or by
spontaneous hydrolysis, results in lyso-phosphatidylcho-
line (LPC). In contrast to PC, which is a membrane form-
ing phospholipid, LPC exerts a lytic action on membranes
[1]. In living cells, LPC usually results from membrane PC
through the enzymatic action of a phospholipase A2
(PLA2), which cleaves the fatty acid from the 2-position of
the glycerol backbone. In the blood, LPC is usually gener-
ated by PLA2 or by the lecithin-cholesterol-acyl-transferase
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(LCAT) from PC present in lipoproteins. The latter
enzyme transfers a fatty acid from PC to cholesterol,
resulting in a cholesterolester and LPC [2]. It has been
reported that triglyceride lipases on endothelial cells are
also able to generate LPC by cleaving the fatty acid ester
bond in the 1 position of glycerophospholipids in lipo-
proteins [3]. Since LPC is membrane lytic, it is predomi-
nantly bound to albumin in the blood and the amount of
free, monomolecular dissolved LPC which is in equilib-
rium with albumin-bound LPC – is very small. However,
even though the equilibrium is shifted strongly towards
albumin-bound LPC, LPC transfer into cells seems to be
fast. It can be taken up by cells rapidly and LPC released
into the blood from membrane PC is quickly bound to
albumin. Thus, the albumin system keeps LPC concentra-
tions in the blood below the lytic concentration but at the
same time provides rapid supply if necessary.
The concentration of LPC in blood plasma of healthy per-
sons usually ranges from 200 to 300 μM [4,5]. Our own
unpublished observations confirmed this range. Sullen-
trop et al. as well as Kuliszkiewicz-Janus et al. have
reported slightly higher ranges of LPC for healthy persons,
varying between 300 and 400 μM [6,7].
It has been observed that ras-transformed cell lines have a
higher PC-turnover and a higher consumption of LPC
than normal cells [8]. Elevated pools of two PC break-
down products, phosphocholine and glycerophospho-
choline, were observed in these experiments [9]. It has
been reported that the ras oncogene product directly or
indirectly causes an increased turnover of PC in mouse
fibroblast cells [10]. Another study indicated that PC
hydrolysis is a target of Ras during the transduction of
growth factor-initiated mitogenic signals [11].
In correspondence to the finding that tumour cells con-
sume more LPC than normal cells, patients with malig-
nant diseases have been found to show changes of the
usual plasma phospholipid pattern. The analysis of
plasma lipids in a group of patients with different kinds of
cancer revealed a general decrease of phospholipids [12].
A group of patients with leukemia, malignant lymphomas
as well as gastrointestinal and renal tumours was found to
have decreased LPC concentrations even at an early stage
of disease compared to healthy persons [6]. In patients
with acute leukemia significantly diminished plasma LPC
concentrations normalised with treatment induced dis-
ease remission [7]. Similar results were observed in
patients with renal cancer. In comparison with healthy
volunteers, both male and female patients had decreased
LPC concentrations in plasma which could be related to
tumour status and metastasis [13].
Based on these findings, we postulated that decreased
plasma LPC concentrations might be a general indicator
for malignant disease and may even allow a predication of
the state of disease. We, therefore, examined the LPC con-
centrations in a group of 59 cancer patients with different
disease entities and varying stages of disease progression.
We determined inflammatory parameters as well as the
nutritional status, since severity of disease is generally
associated with an activation of systemic inflammatory
processes and a deterioration of nutritional status [14].
Results and Discussion
Quantification of LPC by HPTLC – Method validation (see 
Table 1)
The HPTLC is a well-known method in phospholipid
analysis but has to our knowledge not yet been employed
to quantify LPC in human blood plasma. The validation
is therefore a necessary prerequisite for the clinical use of
this method and allows comparison with measurement
results obtained by other means, such as NMR or HPLC.
The advantages of the HPTLC method are its comparable
low cost and the possibility to analyse up to 12 samples in
one run.
Selectivity, linearity, precision and accuracy as well as
limit of quantification, recovery from lipid extraction and
stability of analyte under various storage conditions were
assessed.
The concentration of calibration standards ranged from
60 to 480 μM which were used on 6 different days inde-
pendently to estimate intra- and interday precision and
accuracy same as the QC samples 6 times per day to esti-
mate precision. For QC samples pooled human plasma
with an unknown amount of LPC was used.
Stability of LPC in blood plasma
As there was nothing known about the stability of LPC in
blood plasma under various handling and storing condi-
tions, this part of the validation was a very important
aspect.
The concentration of LPC in blood plasma increases
rather quickly over time if stored at room temperature (+
25°C). The net rise after 48 hours can be estimated at
about 170% of the concentration at zero hours.
Storage of samples in the refrigerator (+ 7°C) does not
affect the concentration of LPC in blood plasma. There is
neither an increase nor decrease to be observed during 72
hours of examination.
Long term storage (6 months) at a temperature of -80°C
does not affect the LPC concentration in plasma sample
aliquots.Lipids in Health and Disease 2007, 6:17 http://www.lipidworld.com/content/6/1/17
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Three freeze and thaw cycles from -80°C to room temper-
ature with immediate deep freezing after sample collec-
tion do not influence the amount of LPC in the plasma
sample.
Stability of samples was assessed for the first time and the
results show that it is possible to store samples by freezing
over large time spans until accumulation of maximum
number of samples for one run which makes the analysis
more efficient than having to process samples straight
away.
The validation of the HPTLC method clearly showed that
it is suitable for sufficiently reproducible, precise and
accurate analysis of LPC in human blood plasma.
Patient study
Patients characteristics (see Table 2)
Age, BMI and the degree of weight change differed consid-
erably among the study subjects. No patient was severely
underweight. The average weight change since tumour
diagnosis was small, while some patients had lost a large
fraction of their body weight and others had gained
weight substantially. Also body composition differed
remarkably among the patients and fractional fat mass
ranged from 9 to 42%, the higher value corresponding to
the upper limit of the normal range for women aged 55 to
64 years [15].
HPO are derived from physiologic lipids by oxidative
damage and HPO blood concentrations are taken to be an
adequate parameter to evaluate oxidative stress [16]. Oxi-
dative damage marks high metabolic activity but also
inflammatory processes. HPO concentrations detected in
our patients in several cases exceeded the normal range
published by an Italian group [17] considerably; this cor-
responds to our previous observations of increased HPO
concentrations in cancer patients [18].
Average CRP concentrations were above the normal range
(> 1 mg/dl) [19] and individual patients had excessively
elevated concentrations indicating varying degrees of acti-
vated inflammatory status.
Albumin is considered to be a negative inflammatory
marker. Average albumin concentrations were normal
[20] but many patients had subnormal amounts and
some patients had very low blood albumin concentra-
tions. This again indicates the varying degrees of systemic
inflammation present in our patient population.
Average LPC was in the range of 200–300 μM, which
could be considered as the normal range from the few
existing studies which included healthy volunteers as well
as patients (see Introduction). As reported previously,
LPC concentrations were found to be diminished in the
blood of patients with leukemia, malignant lymphoma as
well as renal and gastrointestinal tumours. But within our
group the examined LPC concentrations did not differ sig-
nificantly between the sexes or among the tumour diag-
noses (see Table 3). Therefore, the attenuation of LPC
concentrations might occur independent of the type of
malignant disease.
Correlation of LPC with inflammatory and nutritional 
parameters (see Tables 4&5)
The range of LPC concentration observed in our group of
cancer patients was rather large. This broad distribution
justified the investigation of the correlation of LPC with
the parameters of inflammation (CPR, HPO) and nutri-
tional parameters (ECF, albumin, weight loss, fat mass,
BMI).
LPC and parameters of weight
LPC showed no significant correlation with the age of the
patients examined, therefore the LPC concentration in
blood plasma appears to be independent of the age. Nei-
Table 1: Summary of validation results
analyte: lyso-phosphatidylcholine
sample: 75 μl human plasma
selectivity: given
calibration range: 60 – 480 μM
analytical function: quadratic equation (peak area)
linearity: correlation coefficient r ≥ 0.991
precision and accuracy




LOQ 60 μM (inter day accuracy ± 4.7% and precision ± 5.1%)
LOD < 40 μM
Recovery from plasma 79% ± 2%Lipids in Health and Disease 2007, 6:17 http://www.lipidworld.com/content/6/1/17
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ther BMI nor relative fat mass correlated with the LPC con-
centration. In contrast, LPC correlated with the relative
change in body weight as well as with HPO, albumin, CRP
and ECF. We found LPC to correlate directly with the
weight change since cancer diagnosis considering the
whole group of patients (r = 0.3099). Narrowing down to
a subgroup of patients with severe weight loss since first
diagnosis reveals this interrelation even stronger (r =
0.5315). We conclude that LPC concentrations may not
be influenced by body weight itself. Underweight or over-
weight do not allow any predication of LPC concentra-
tions, but if a change in weight has occurred, the LPC is
prone to have changed, too. That means LPC concentra-
tion is lowered when a loss of weight – in our patients
group caused by the cancer disease – could be observed.
In consequence, it might be possible that a low LPC con-
centration is an indicator for the actual process of losing
weight and LPC concentrations might return to normal
when the weight stabilises even if the patient has reached
underweight.
LPC and parameters of inflammation
Since disease-related weight loss is known to often be
associated with inflammatory processes, our findings
regarding markers of inflammation and metabolic activity
support the observed relationship between LPC and
weight loss. First of all, we found HPO to correlate with
LPC in the whole group and even stronger in the group of
patients with breast cancer (r = -0.811). Regarding only
the patients with a BMI equal to or lower than 21 which is
only a small subgroup in our investigation, we also see a
strong correlation between HPO and LPC (r = -0.833)
leading us to consider whether unduly high metabolic
activity that might lead to weight loss in cancer patients is
indicated by decreased LPC concentrations, too.
Furthermore, we found CRP to correlate negatively with
LPC concentration (r = -0.482). CRP higher than 1 mg/dl
is generally considered as status of inflammation. Restrict-
ing the patients' group to those who had an elevated CRP
concentration in their blood, we observed a slightly
weaker correlation between LPC and CRP than in the
whole group. This might be explained by the higher math-
ematical influence here of one single value, 21.1, which is
the only one greater than 10. Regarding only patients with
elevated HPO concentrations we find a stronger correla-
tion between LPC and CRP as well as in the subgroups of
patients with severe weight loss and with low plasma
Table 3: Average LPC concentrations classified by sex and tumour diagnosis with calculation of statistically significant differences 
between means
subgroup n average LPC conc. (μM) standard deviation (μM) range (μM) significant difference*
sex male 26 202 53 89–305 no
female 33 212 64 109–362 no
cancer type breast 17 205 60 128–239
prostate 6 198 47 122–249
lung 5 177 38 118–214 no
lymphoma 8 227 80 98–356
gastrointestinal 12 194 53 89–270
other2 11 232 60 135–362
2 ovaries, kidney, bladder, uterus, mesothelioma, myeloma, aggressive fibromatosis, oligodendroglioma
* p < 0.05
Table 2: Patients' characteristics: summary of the examined parameters with analysis of distribution
parameter average range
age (years)1 60.6 ± 10 32 to 78
performance status1 1.5 ± 0.7 0 to 3
BMI (kg/m2) 25.6 ± 4.1 18 to 36
ΔFD (% BW) -1.9 ± 11.8 -28.8 to + 23.3
FM (% BW) 23.7 ± 8.3 9.4 to 42.4
HPO (U.FORT)1 463 ± 150 156 to 938
CRP (mg/dl)1 1.7 ± 3 0.5 to 21.1
ECF (%TBW) 48.8 ± 4 41 to 60
albumin (g/dl)1 3.8 ± 0.6 1.7 to 5.7
LPC (μM) 207 ± 59 89 to 362
1non-normal distributionLipids in Health and Disease 2007, 6:17 http://www.lipidworld.com/content/6/1/17
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albumin concentrations (r = -0.713). This supports our
assumption that parameters of inflammation, weight loss
and LPC are clearly interrelated. Just about not significant
as defined by general convention (p < 0.05) but still worth
considering are the correlations between LPC and CRP in
the subgroups of breast cancer patients, lymphoma
patients and patients with gastrointestinal cancers.
This leads us to speculate that LPC concentrations are
associated with a high metabolic activity and activated
inflammatory processes and thus with syndromes typi-
cally associated with disease severity. LPC concentrations
might thus be a general indicator of disease severity.
ECF and albumin
Another parameter associated with inflammation and
general unfavourable state of health is the extra cellular
fluid in body tissues as percentage of total body water.
High ECF in relation to intra cellular fluid is often caused
by inflammatory processes that augment vascular perme-
ability and lead to local oedema, ascites or pleural effu-
sions [21]. Another cause can be a disturbed osmotic
Table 4: Correlation between LPC concentrations and the examined parameters (n = 59)
parameter correlated with LPC correlation coefficient r p significant*
age (years)1 -0.159 0.229 no
performance status1 -0.12 0.365 no
BMI (kg/m2) 0.0097 0.9416 no
FM (% BW) 0.2483 0.058 no
ΔFD (% BW) 0.3099 0.0169 yes
HPO (FORT units)1 -0.493 0.0000 yes
CRP (mg/dl)1 -0.482 0.0000 yes
ECF (% TBW) -0.5531 0.0000 yes
albumin (g/dl)1 0.454 0.0000 yes
1non-normal distribution; correlation tests performed with Spearman rank correlation test
* p < 0.05
Table 5: Correlation between LPC levels and the examined parameters in various subgroups
subgroup Δ FD vs. LPC HPO1 vs. LPC CRP1 vs. LPC ECF vs. LPC albumin1 vs. LPC
breast (n = 17) r = 0.2646 -0.811 -0.473 -0.666 0.325
p = 0.3047 0.0000* 0.0537 0.0035* 0.196
prostate (n = 6) -0.347 -0.257 -0.507 -0.534 0.638
0.5 0.658 0.297 0.275 0.175
lung (n = 5) -0.291 -0.7 0.000 0.51 -0.7
0.634 0.233 1.000 0.38 0.233
lymphoma (n = 8) 0.777 -0.595 -0.655 -0.731 0.401
0.0233* 0.102 0.0716 0.0394* 0.29
GIT (n = 12) 0.382 0.055 -0.567 -0.514 0.653
0.22 0.852 0.0512 0.0873 0.0203*
other (n = 11) 0.258 -0.482 -0.397 -0.48 0.693
0.443 0.124 0.21 0.135 0.0321*
Δ FD>10%loss (n = 
15)
0.5315 -0.136 -0.575 -0.6612 0.386
0.0414* 0.62 0.0241* 0.0153* 0.15
BMI ≤ 21 (n = 9) 0.422 -0.833 0.008 -0.828 0.51
0.258 0.0019* 0.948 0.0059* 0.138
CRP > 1 (n = 22) 0.337 -0.301 -0.427 -0.4691 0.33
0.125 0.17 0.0467* 0.0276* 0.131
HPO ≥ 500 (n = 18) 0.014 -0.29 -0.519 -0.318 0.384
0.956 0.238 0.0269* 0.198 0.114
alb. < 3,5 (n = 10) 0.217 -0.345 -0.713 -0.583 0.428
0.546 0.309 0.0186* 0.0769 0.199
1non-normal distribution; correlation tests performed with Spearman rank correlation test
* significant correlation (p < 0.05)
Upper number in cells corresponds to correlation coefficient r of respective pair analysis, lower number corresponds to p (as displayed in first cell)Lipids in Health and Disease 2007, 6:17 http://www.lipidworld.com/content/6/1/17
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balance between the blood and the tissue compartment. If
the osmotic pressure of the blood is lowered, more liquid
is pushed out of the vessels into the surrounding tissues
[22]. Osmotic pressure in the blood is held up by its con-
tent of proteins, 60% thereof being albumin. An albumin
deficiency can therefore cause oedema and ascites. Albu-
min is considered to be an inverse inflammatory marker,
decreasing when inflammation is present [23]. We found
ECF to show strong inverse correlations with LPC concen-
trations. Both negatively in the whole group as even
stronger in several subgroups like the breast cancer (r = -
0.666) and the lymphoma patients. Same can be said for
the subgroups of patients with more than 10% weight loss
since first diagnosis and patients with low BMI as well as
patients with elevated CRP. Patients with high ECF have
lowered LPC concentrations. ECF also correlated nega-
tively with albumin concentrations and albumin corre-
lated directly with LPC (r = 0.454). Thus, patients with
lowered albumin had diminished LPC amounts in their
blood. Since albumin is a regulating factor both for ECF
because of the osmotic pressure balance, and for LPC hav-
ing 2.8 binding sites for this molecule [24], one could
conclude that the relationship between LPC and ECF is
solely explained by their common regulator albumin. If
we only consider patients with albumin between 4 and 5
g/dl (n = 22) we do not observe any correlation between
ECF and LPC which would confirm that LPC and ECF
only interrelate because of their dependency on albumin.
On the other hand, we do not observe significant correla-
tions between LPC and albumin where we find them
between LPC and ECF, for example in the breast cancer
group. Therefore, we suppose that the interrelation of LPC
and ECF is not exclusively accounted for by albumin.
Conclusion
For the first time, we provided evidence that there exists a
relationship between LPC concentrations in blood
plasma and both weight change and inflammatory proc-
esses in malignant diseases. Reason for these observations
might be the observed rapid PL-turnover of tumour cells
resulting in an increased LPC consumption from the
blood plasma. Since an increased turnover of membrane
PL appears to be associated with tumour progression and
metastasis, LPC blood concentrations might well be a
strong marker for tumour progression. Since we did not
have many patients in our examined group who suffered
from severe weight loss or underweight, the observations
we made concerning the body weight and its relationship
with LPC should be confirmed in a study with a group of
patients where weight loss occurs more often and more
severe. Further, the effects of a nutritional supplementa-
tion with phospholipids on the weight loss of cancer
patients should be investigated.
Methods
Patients
We studied 59 patients (33 women, 26 men). All partici-
pants gave informed written consent. The compliance of
study protocol with the Helsinki Declaration was
approved by the Ethics Committee of Freiburg University.
Patients were recruited as in-patients from the Depart-
ment of Medical Oncology at Tumor Biology Center
Freiburg between November 2005 and February 2006.
Inclusion criteria were: age >18 years, diagnosis of solid
tumour and performance status <3. Mean age of the
patients was 60.6 years, mean body mass index was 25.6
kg/m2 and mean performance status was 1.5 (see Table 2).
Patients differed considerably with respect to BMI (and
thus nutritional status) and performance status (see Table
2) as was intended to allow valid correlation analyses. All
patients had been diagnosed with a solid tumour (see
Table 3) and had been receiving varying treatments.
Blood sampling and analysis
Postabsorptive blood samples were collected in EDTA-
containing tubes for routine analysis, plasma was sepa-
rated by centrifugation and analysed immediately or
stored in aliquots at -80°C until LPC analysis. CRP was
determined using a sandwich immunoassay (VITROS
Chemistry Products CRP Slides; Ortho-Clinical Diagnos-
tics Inc., New York, USA) and albumin using a colorimet-
ric assay (VITROS Chemistry Products ALB Slides; Ortho-
Clinical Diagnostics Inc., New York, USA).
Hydrogen peroxides were determined from whole blood
by a photometric assay containing Fenton's reagent
(FORT test, Micro-Medical Instrumente GmbH, König-
stein, Germany). For this assay, 20 μl of capillary blood
were taken from the patients' finger, mixed with the reac-
tion solution, centrifuged and transferred to a cuvette for
photometric measurement at 505 nm wavelength
(FORM-CR 2000, Micro-Medical Instrumente GmbH,
Königstein, Germany). Results are expressed as arbitrary
FORT units (1 unit corresponding to 7.6 μMol/l hydrogen
peroxide). The test is reliable with an intra-assay Vc<5%
[18]. The normal range in healthy volunteers has been
reported as 230–310 units [17].
Examination of nutritional status
Participants were weighed and measured and BMI was cal-
culated as (weight in kg)/(height in m)2.
Bioelectrical impedance analysis (BIA) estimates body
water from whole body impedance against an alternating
high-frequency current. For the test a low voltage is
applied to wrist and ankle via self-adhering electrodes
(Fresenius Kabi AG, Medical Devices, Bad Homburg, Ger-
many) and an alternating current produced of about 0.8
mA [13]. The analysis was performed using a calibratedLipids in Health and Disease 2007, 6:17 http://www.lipidworld.com/content/6/1/17
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impedance spectrum analyzer (Hydra 4200, Xitron Tech-
nologies Inc., San Diego, USA), an alternating current at
multiple frequencies from 5 to 1000 kHz and non-linear
regression analysis using the Cole-Cole method. Further
parameters obtained are fat free mass (FFM), total body
water (TBW) as well as intracellular (ICF) and extracellu-
lar water (ECF) [25].
LPC analysis
In order to analyse LPC in blood plasma, samples had to
be subjected to lipid extraction prior to HPTLC analysis.
Extraction was performed according to a modified
method of Bligh and Dyer [26] as follows: 75 μl of the
serum sample was mixed with 925 μl 0.9% NaCl aqueous
solution as well as 500 μl of each of the five calibration
standards with 500 μl 0.9% NaCl aqueous solution. Then,
3 times in repetition, 2 ml CHCl3/MeOH (2:1 v/v) were
added to each vial, vials were shaken for 5 min. at 1000
rpm, then centrifuged at 4°C for 10 min. at 3000 rpm
(2060 × g) and the CHCl3 layer was transferred to a clean,
dry glass vial. The collected CHCl3 phases were evapo-
rated at 40°C under a stream of nitrogen. Dry serum
extracts were dissolved in 75 μl, calibration standards in
500  μl of Hexan/Isopropanol/H2O (40/50/8 v/v/v) by
shaking again for 5 min. at 1000 rpm. HPTLC silica gel
plates (Merck, 20 × 10 cm) were preconditioned by a
blanc run in the mobile phase same as used for the later
analysis: CHCl3/MeOH/H2O/NH3 (65/24/4/0,4 v/v/v/v)
and dried on a heating plate at 180°C.
Twelve μl of each calibration standard and of each sample
were applied to the preconditioned plate as bands of 8
mm width with the Camag Automatic Sampler TLC III.
Each plate was developed with the above mentioned
mobile phase in a closed glass tank after letting the solvent
equilibrate in the tank. Run time was about 16 min. with
10 cm distance (the whole length of the plate). After
development plates were dried on a heating plate at
180°C for 10 min. For detection purposes the plates were
stained with a copper sulphate/phosphoric acid solution
(14,7% w/v; 10% v/v) by 3 times repeated immersion for
2 sec. with the help of the automatic Camag Immersion
device III and then dried for 6 min. at 160°C in the oven
of an GC apparatus. After staining, the plates could be
interpreted by scanning with a Camag TLC-Scanner II
(CATS-Software, version 3.16) with a tungsten bulb at 530
nm in absorption/reflection mode.
Results were calculated from the calibration curve estab-
lished by the 5 calibration standards, solutions of LPC
(Sigma, Germany) in 0.9% NaCl aqueous solution, rang-
ing from 60 to 480 μM in concentration.
Statistics
The statistical analysis was performed with SigmaStat 3.1
(Systat Software Inc., USA, 2004).
Analysis of differences was performed with Student's t-
test. Correlation tests were performed with Pearson's cor-
relation test if the parameters were normally distributed,
all others were performed with the Spearman rank corre-
lation test.
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